araag2/HINT huggingface dataset:
Clinical trial NCT01866163 (phase 3, status: completed)
Conditions: psoriasis vulgaris
ICD codes: L40.0
Drugs: leo 90100, vehicle
SMILES: [H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  A clinical diagnosis of psoriasis vulgaris of at least 6 months duration involving the
             trunk and/or limbs

          -  Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and
             skin folds) involving 2-30% of the Body Surface Area (BSA)

          -  An Investigator's Global Assessment of disease severity (IGA) of at least mild at Day
             0 (Visit 1)

          -  A modified PASI (m-PASI) score of at least 2 at Day 0 (Visit 1)

          -  A target lesion of a minimum of 5 cm at its longest axis and preferably not located on
             the extensor surface on an elbow or knee, scoring at least 1 for each of redness,
             thickness and scaliness, and at least 4 in total by the Investigator's Assessment of
             Severity of the Target Lesion

        Exclusion Criteria:

          -  Systemic treatment with biological therapies, whether marketed or not, with a possible
             effect on psoriasis vulgaris within the following time periods prior to randomisation:

               -  etanercept - within 4 weeks prior to randomisation

               -  adalimumab, infliximab - within 8 weeks prior to randomisation

               -  ustekinumab - within 16 weeks prior to randomisation

               -  other products - within 4 weeks/5 half-lives prior to randomisation (whichever is
                  longer)

          -  Systemic treatment with all other therapies with a possible effect on psoriasis
             vulgaris (e.g., corticosteroids, retinoids, methotrexate, ciclosporin and other
             immunosuppressants) within 4 weeks prior to randomisation.

          -  Subjects who have received treatment with any nonmarketed drug substance (i.e. a drug
             which has not yet been made available for clinical use following registration) within
             4 weeks/5 half-lives (whichever is longer) prior to randomisation.

          -  PUVA therapy within 4 weeks prior to randomisation.

          -  UVB therapy within 2 weeks prior to randomisation.

          -  Topical anti-psoriatic treatment on the trunk and limbs (except for emollients) within
             2 weeks prior to randomisation.

          -  Topical treatment on the face, scalp and skin folds with corticosteroids, vitamin D
             analogues or prescription shampoos within 2 weeks prior to randomisation.

          -  Planned initiation of, or changes to, concomitant medication that could affect
             psoriasis vulgaris (e.g. beta blockers, antimalarial drugs, lithium, ACE inhibitors)
             during the trial.

          -  Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis.

          -  Previously randomised in this trial or any previously conducted trial of LEO 90100.
Clinical trial NCT00152243 (phase 3, status: completed)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: uft (uracil, tegafur)
SMILES: FC1=CN(C2CCCO2)C(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age 20 to 75

          -  Performance status 0 , 1, or 2 (ECOG)

          -  Hematopoietic WBC ≥ 4,000/mm^3 Platelet ≥ 100,000/mm^3

          -  Hepatic AST and ALT ≤ 2 times upper limit of normal(ULN) Total bilirubin ≤ 1.5 times
             ULN

          -  Renal BUN ≤1.5 times ULN Creatinine ≤ 1.5 times ULN

        Exclusion Criteria:

          -  Prior anticancer treatment
Clinical trial NCT00306384 (phase 3, status: completed)
Conditions: diabetes mellitus
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: alogliptin
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Females of childbearing potential who are sexually active must agree to use adequate
             contraception, and can neither be pregnant nor lactating from Screening throughout the
             duration of the study.

          -  Type 2 diabetes mellitus and was enrolled in one of the following 7 controlled Phase
             III studies. The study will be open to all patients who completed one of these studies
             through the end-of-treatment visit:

               -  SYR-322-PLC-010 - NCT00286455

               -  SYR-322-SULF-007 - NCT00286468

               -  SYR-322-MET-008 - NCT00286442

               -  SYR-322-TZD-009 - NCT00286494

               -  SYR-322-INS-011 - NCT00286429

               -  01-05-TL-322OPI-001 - NCT00328627

               -  01-06-TL-322OPI-002 - NCT00395512

          -  Alanine aminotransferase less than or equal to 3 times the upper limit of normal and
             serum creatinine less than or equal to 2.0 mg per dL.

          -  Able and willing to monitor own blood glucose concentrations with a home glucose
             monitor.

          -  No major illness or debility that in the investigator's opinion prohibits the patient
             from completing the study.

        Exclusion Criteria

          -  The occurrence of any adverse event or condition during the controlled Phase III
             studies, which, in the opinion of the investigator, should exclude the patient from
             participating in the open-label extension.

          -  Is required to take or intends to continue taking any disallowed medication, any
             prescription medication, herbal treatment or over-the counter medication that may
             interfere with evaluation of the study medication, including:

               -  Weight-loss drugs

               -  Investigational antidiabetics, additional dipeptidyl peptidase-4 (DPP-4) and
                  glucagon-like peptide-1 (GLP 1) inhibitors

               -  Incretin Mimetics,

               -  Oral or systemically injected glucocorticoids.
Clinical trial NCT00705822 (phase 3, status: terminated)
Conditions: prostatic neoplasms
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1
Drugs: docetaxel + estramustine + hydrocortisone, docetaxel + prednisone
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1
Reason stopped: 
    low recruitment rate
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological confirmation of prostate adenocarcinoma

          -  Advanced prostate carcinoma.

          -  Previous treatment with hormones

          -  Levels of testosterone < 50 ng/dL

          -  Good hematological, liver and kidney function

          -  Previous treatment with surgery or radiotherapy, at least 4 weeks since end of
             treatment is allowed (the patient should have been recovered from any side effects.

        Exclusion Criteria:

          -  Previous chemotherapy (estramustine included).

          -  Second line hormonotherapy (oestrogens, gestagens, ketoconazole, ...included)

          -  Previous treatment with radiotherapy (isotopes) or previous radiotherapy over > 25% of
             the marrow

          -  Any malignant process with a free disease interval under 5 years, exception done to
             non-melanoma skin cancer.

          -  Concomitant serious diseases

          -  Concomitant treatment with any other neoplassic therapy (exception done to LHRH
             agonists and/or biphosphonates).

          -  Contraindication for the treatment with estramustine.

          -  Previous history of pulmonary embolism, thromboembolic disease, previous treatment
             with anticoagulants (except aspirin), active thrombophlebitis or hypercoagulation.

          -  Previous history of pulmonary spillage or ascitis.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00062595 (phase 3, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: phylloquinone (k1), menatetranone (mk4)
SMILES: CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)C2=C(C=CC=C2)C1=O
Eligibility criteria:

        -  Female, 5 years postmenopause.

          -  Ambulatory.

          -  Community dwelling.

          -  Able to ingest calcium and vitamin D supplements.

          -  Willing to restrict vitamin K intake.

          -  Stable thyroid dose if appropriate.

          -  No history of hyperthyroidism, hyperparathyroidism or other metabolic bone diseases.

          -  Absence of hardware in hip and spine.

          -  History of malignancy within the last five years.

          -  Not currently using coumadin or warfarin.

          -  Vitamin D supplements must be less than 800 IU daily.

          -  Have not used estrogen or other bone-altering medications (see list in study
             description) within the last year.

          -  No history of liver disease or malabsorption.

          -  No known allergy to vitamin K.

          -  Have not participated in an investigational drug trial within the last month.
Clinical trial NCT00616772 (phase 3, status: completed)
Conditions: coronary artery disease, coronary heart disease, dyslipidemia
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118, I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: abt-335, placebo
SMILES: CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with mixed dyslipidemia

          -  Qualifying cIMT thickness

        Exclusion Criteria:

          -  Patients with certain chronic or unstable medical conditions.

          -  Patients with unstable dose of medications or receiving coumadin, cyclosporine, or
             certain other medications

          -  Pregnant or lactating women or women intending to become pregnant

          -  Patients with diabetes mellitus that is poorly controlled
Clinical trial NCT01003184 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: exenatide once weekly, insulin detemir
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have suboptimal glycaemic control as evidenced by an HbA1c 7.1% to 10.0%, inclusive

          -  Have a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive

          -  Are receiving metformin at a stable dose (consistent with country specific
             requirements) of a minimum of 1000mg for at least 3 months prior to start start OR are
             receiving metformin at a minimum dose (consistent with country specific requirements)
             of 1000mg and sulphonylurea (as separate medications not as a fixed dose combination)
             at stable doses for 3 months prior to study start

        Exclusion Criteria:

          -  Have any contraindication for the OAD that they have been using

          -  Have a known allergy or hypersensitivity to insulin detemir, exenatide or excipients
             contained in these agents

          -  Have been treated within 4 weeks of screening with systemic glucocorticoid therapy by
             oral, intravenous (IV) or intramuscular (IM) route, or are regularly treated with
             potent, inhaled intranasal steroids that are known to have a high rate of systemic
             absorption. Exceptions to this criterion include patients who are receiving
             glucocorticoid therapy for corticotropic hypopituitary deficiency (e.g. Addison
             disease)

          -  Have been treated with drugs that promote weight loss, within 3 months of screening

          -  Have been treated for longer than 2 weeks with any of the following excluded
             medications within 3 months prior to screening: insulin, alpha-glucosidase, Byetta®
             (exenatide BID formulation), thiazolidinediones (TZD), dipeptidyl peptidase (DPP)-4
             inhibitors

          -  Have previously completed or withdrawn from this study or any other study
             investigating exenatide QW

          -  Have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication at the time of study entry

          -  Are currently enrolled in, or discontinued within the last 30 days from, a clinical
             trial involving an off-label use of an investigational drug or device (other than the
             study drug/device used in this study), or concurrently enrolled in any other type of
             medical research judged not to be scientifically or medically compatible with this
             study
Clinical trial NCT00487435 (phase 3, status: completed)
Conditions: pain, osteoarthritis, low back pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52, M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019, M54.50, M54.51, M54.59
Drugs: tapentadol (cg5503) extended release (er)
SMILES: CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Non-lactating female subjects (Sexually active women must be postmenopausal,
             surgically sterile, or practicing an effective method of birth control [e.g.,
             prescription oral contraceptives, contraceptive injections, intrauterine device,
             double barrier method, contraceptive patch, male partner sterilization] before entry
             and throughout the trial. Female patients of childbearing potential must have a
             negative pregnancy test at screening.)

          -  Completion of the expected double-blind treatment period of the pivotal Tapentadol
             (CG5503) Phase 3 trials in osteoarthritis (R331333-PAI-3008, KF5503/11) or low back
             pain (R331333-PAI-3011, KF5503/23), or completion of the 1-year treatment period of
             the safety CG5503 Phase 3 trial in the non-European sites (R331333-PAI-3007,
             KF5503/24)

          -  Must be willing to take Tapentadol (CG5503) extended release (ER) and the rescue
             medication supplied for the duration of the trial

        Exclusion Criteria:

          -  History of alcohol and/or drug abuse, life-long history of seizure disorder or
             epilepsy, any of the following within the past year: mild/moderate traumatic brain
             injury, stroke, transient ischemic attack, or brain neoplasm

          -  Severe traumatic brain injury within the past 15 years

          -  Uncontrolled hypertension (repeated systolic blood pressure >160 mmHg or diastolic
             blood pressure >95 mmHg)

          -  Severely impaired renal function

          -  Moderately or severely impaired hepatic function

          -  Patients taking neuroleptics, monoamine oxidase inhibitors, or tricyclic
             antidepressants within 14 days prior to screening.
Clinical trial NCT00056407 (phase 3, status: completed)
Conditions: neoplasms, prostate
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: dutasteride, placebo
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Informed consent to participate in study.

          -  Have had a single negative prostate biopsy within 6 months prior to enrollment in
             study.

          -  Have a PSA (prostate specific antigen) between 2.5 and 10 if 50-60 years of age; or a
             PSA between 3.0 and 10 if over age 60.

          -  Ability and will to participate in study for 4 years.

        Exclusion criteria:

          -  More than one previous negative prostate biopsy.

          -  History of prostate cancer.

          -  Previous prostate surgery.

          -  Inability to urinate requiring the need of a catheter during the previous 2 years.

          -  Any condition (other than benign prostatic hypertrophy) which may result in urinary
             symptoms or changes in urine flow rate.

          -  Cancer within previous 5 years (other than basal or squamous cell cancers of the
             skin).

          -  Any unstable serious medical condition.

          -  Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
             (Avodart), testosterone, or drugs that can block the action of male hormones.
Clinical trial NCT00328718 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: montelukast (5mg qd), salmeterol/fluticasone propionate inhalation powder (50/100mcg bid)
SMILES: OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(\C=C\C2=NC3=C(C=CC(Cl)=C3)C=C2)=C1, OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(\C=C\C2=NC3=C(C=CC(Cl)=C3)C=C2)=C1
Eligibility criteria:

        Inclusion criteria:

          -  Diagnosis of asthma for at least 6 months (per American Thoracic Society [ATS]
             definition).

          -  Best forced expiratory volume in one second (FEV1) between 55% and 80% of predicted
             normal.

          -  More than or 12% FEV1 reversibility following inhalation of salbutamol.

          -  Must also be symptomatic on short-acting beta-agonists.

          -  Must not have used inhaled corticosteroids over the previous month or LTRAs
             (Leukotriene antagonists)over the previous 2 weeks.

        Exclusion criteria:

          -  Hospital admission for asthma within 3 months prior to Visit 1.

          -  Sinus, middle ear, oropharyngeal, upper or lower respiratory tract infections within
             two weeks immediately preceding Screening Visit 1.

          -  Oral or parenteral steroid therapy in the last 12 weeks, or more than 3 courses in the
             last 6 months.
Clinical trial NCT00549939 (phase 3, status: completed)
Conditions: neurogenic urinary bladder
ICD codes: G98.0, K59.2, M48.061, M48.062
Drugs: alfuzosin, placebo
SMILES: COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N(C)CCCNC(=O)C1CCCO1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient with elevated detrusor Leak Point Pressure (LPP) of neuropathic etiology and
             Detrusor LPP ≥ 40 cm H2O and < 100 cm H2O.

        Exclusion Criteria:

          -  Urological surgery in the last 4 months prior to the study,

          -  Patients who have urethral dilatation in the last 3 months prior to the baseline
             urodynamic assessment,

          -  α-blocker therapy in the last 4 weeks prior to the baseline urodynamic assessment,

          -  Detrusor injections of botulinum toxin in the last 6 months,

          -  Urological diseases/conditions other than functional bladder obstruction of
             neuropathic etiology that can lead to upper urinary tract dilatation (e.g., bladder
             anomalies, ureterocele),

          -  History of intolerance to α-blocker therapy,

          -  Orthostatic hypotension,

          -  History of risk factors for Torsade de pointes (e.g., family history of Long QT
             Syndrome).

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00688688 (phase 3, status: completed)
Conditions: urinary bladder, overactive
ICD codes: N32.81
Drugs: mirabegron, tolterodine, placebo to mirabegron, placebo to tolterodine
SMILES: NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1, CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C, NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1, CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is willing and able to complete the micturition diary and questionnaires
             correctly

          -  Patient has symptoms of overactive bladder for ≥ 3 months

          -  Patient experiences frequency of micturition on average ≥ 8 times per 24-hour period
             during the 3-day micturition diary period

          -  Patient must experience at least 3 episodes of urgency (grade 3 or 4) with or without
             incontinence, during the 3-day micturition diary period

        Exclusion Criteria:

          -  Patient is breastfeeding, pregnant, intends to become pregnant during the study, or of
             childbearing potential, sexually active and not practicing a highly reliable method of
             birth control

          -  Patient has significant stress incontinence or mixed stress/urge incontinence where
             stress is the predominant factor

          -  Patient has an indwelling catheter or practices intermittent self-catheterization

          -  Patient has diabetic neuropathy

          -  Patient has evidence of a symptomatic urinary tract infection, chronic inflammation
             such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or
             previous or current malignant disease of the pelvic organs

          -  Patient receives non-drug treatment including electro-stimulation therapy

          -  Patient has severe hypertension

          -  Patient has a known or suspected hypersensitivity to tolterodine, other
             anticholinergics, YM178, other beta-adrenoreceptor (ß-AR) agonists, or lactose or any
             of the other inactive ingredients

          -  Patient has been treated with any investigational drug or device within 30 days (90
             days in the UK for all clinical studies except 178-CL-046)

          -  Patient had an average total daily urine volume > 3000 mL as recorded in the 3-day
             micturition diary period

          -  Patient has serum creatinine >150 umol/L, aspartate aminotransferase (AST) and/or
             alanine aminotransferase (ALT) > 2x upper limit of normal range (ULN), or
             gamma-glutamyl transpeptidase (γ-GT) > 3x ULN

          -  Patient has a clinically significant abnormal electrocardiogram (ECG)
Clinical trial NCT01202227 (phase 3, status: completed)
Conditions: spinal cord diseases, spinal cord injuries, neuralgia, pain
ICD codes: G95.9, G32.0, G95.89, P15.8, T07.XXXS, P12.89, P13.1, P14.3, T07.XXXA, T07.XXXD, G50.0, M54.81, B02.22, M79.2, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: pregabalin
SMILES: NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

        Inclusion criteria for subjects to be shifted from Study A0081107

          -  Subjects who completed the 18-week study period in Study A0081107 conducted for
             chronic neuropathic pain after spinal cord injury;

          -  Subjects who completed assessments of all efficacy endpoints until the end of the
             treatment phase of the preceding Study A0081107 (V7);

        Inclusion criteria for subjects to be new participants in this study

          -  Subjects with central neuropathic pain after stroke or multiple sclerosis;

          -  At least 6 months have passed after the onset of central neuropathic pain;

          -  Pain VAS at least 40mm in Visit 1 and Visit 2;

        Exclusion Criteria:

          -  Creatinine clearance < 60 mL/min;

          -  Platelet count < 100 × 103/mm3 ; White blood cell (WBC) count < 2500 / mm3; Neutrophil
             count < 1500/ mm3;

          -  Subjects who are expected to require surgery during the trial;